<DOC>
	<DOCNO>NCT00077558</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fludarabine , work different way stop cancer cell divide stop grow die . 3-AP may help fludarabine kill cancer cell make sensitive drug . PURPOSE : This phase I trial study side effect best dose fludarabine give together 3-AP treating patient relapse refractory acute leukemia , chronic leukemia , high-risk myelodysplastic syndrome .</brief_summary>
	<brief_title>3-AP Followed By Fludarabine In Treating Patients With Relapsed Refractory Acute Chronic Leukemia High-Risk Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility tolerability 3-AP ( Triapine^® ) follow fludarabine patient relapse refractory acute chronic leukemia high-risk myelodysplastic syndrome . - Determine toxic effect regimen patient . - Determine maximum tolerate dose regimen patient . OUTLINE : This multicenter , dose-escalation study fludarabine . Patients stratify accord disease ( acute leukemia myelodysplastic syndrome [ MDS ] v chronic lymphocytic leukemia prolymphocytic leukemia ) . Patients assign 1 2 treatment group . - Group 1 ( chronic lymphocytic leukemia prolymphocytic leukemia ) : Patients receive 3-AP ( Triapine^® ) IV 4 hour fludarabine IV 30 minute day 1-5 . Cohorts 3-6 patient receive escalate dos fludarabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , 10 additional patient treat dose level . - Group 2 ( acute leukemia MDS ) : Patients receive 3-AP IV continuously 24 hour day 1 . Beginning within 4 hour completion 3-AP , patient receive fludarabine IV 30 minute day 2-6 . In group , treatment repeat every 3 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 3-34 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Highrisk myelodysplastic syndrome ( MDS ) , include refractory anemia excess blast chronic myelomonocytic leukemia International Prognostic Scoring System ( IPSS ) score least 1.5 base following : More 10 % marrow blast Cytopenias least 2 lineage Adverse cytogenetics Acute myeloid leukemia ( AML ) All subtypes , include MDS/AML treatmentrelated ( secondary ) AML Acute lymphoblastic leukemia Acute progranulocytic leukemia Ineligible arsenic therapy Chronic myelogenous leukemia Accelerated phase blastic crisis Chronic lymphocytic leukemia Prolymphocytic leukemia Received ineligible establish curative regimen , include stem cell transplantation Acute chronic leukemia must relapse and/or refractory progressive disease since last therapy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic No history hemolytic anemia grade 2 great No known glucose6phosphate dehydrogenase ( G6PD ) deficiency G6PD screening require highrisk group ( i.e. , patient African , Asian , Mediterranean origin/ancestry ) Hepatic SGOT SGPT great 2.5 time normal Bilirubin great 2 mg/dL No chronic hepatitis Renal Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular No active heart disease No myocardial infarction within past 3 month No severe coronary artery disease No arrhythmia ( atrial flutter fibrillation ) require medication No uncontrolled congestive heart failure Pulmonary No dyspnea rest minimal exertion No severe pulmonary disease require supplemental oxygen Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No neuropathy grade 2 great No active uncontrolled infection Infections active treatment control antibiotic allow No lifethreatening illness No psychiatric illness would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics At least 1 week since prior hematopoietic growth factor ( e.g. , epoetin alfa , filgrastim [ GCSF ] , sargramostim [ GMCSF ] , interleukin3 , interleukin11 ) No concurrent immunotherapy Chemotherapy Recovered prior chemotherapy ( great grade 1 chronic toxic effect ) At least 72 hour since prior hydroxyurea At least 3 week since prior myelosuppressive cytotoxic agent ( 6 week mitomycin nitrosoureas ) No 12 prior course fludarabine No 3 prior cytotoxic chemotherapy regimens No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy At least 2 week since prior radiotherapy No concurrent radiotherapy Surgery Not specify Other At least 1 week since prior nonmyelosuppressive treatment No 4 prior induction regimens No concurrent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>